HD Immune
- Biotech or pharma, therapeutic R&D
Antibody Therapy for Huntington Disease
The aim of HD Immune is the development of therapeutic human antibodies targeting the toxic and mutated form of HTT protein (mtHTT) which is the cause and driver of the hereditary neurodegenerative disorder, Huntington’s disease (HD, Chorea Huntington). HD is a rare neurological disease with a fatal outcome that cannot be cured since there are no drugs available, recent clinical trials based on HTT gene expression regulation did not reach primary endpoints. Because there is an unmet medical need, we develop an antibody drug that can slow down HD progression and delay clinical symptoms.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}